Clinical Trials

Inclusion Criteria:  

• Participant must have histologically or cytologically confirmed, locally advanced or  metastatic non-small cell lung cancer (NSCLC) not amenable to curative therapy  -Participant must have a tumor that was previously determined to have exon 19 deletions  (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug  administration (FDA)-approved or other validated test in a clinical laboratory  improvement amendments (CLIA) certified laboratory (sites in the United states [US])  or an accredited local laboratory (sites outside of the US) in accordance with site  standard of care. The biopsy must have been obtained at or after the diagnosis of  advanced disease.
• Unstained tumor tissue (in a quantity sufficient to allow for central analysis of epidermal growth factor receptor (EGFR) mutation status, see Laboratory Manual) and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase  chain reaction [ddPCR], and pharmacogenomic analysis), both collected at or after the  diagnosis of locally advanced or metastatic NSCLC, must be provided.
• Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level.
• Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated.  Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be  acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy.

Exclusion Criteria:

• Participant has received any prior systemic treatment for locally advanced or  metastatic disease (adjuvant or neoadjuvant therapy is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease).
• Participant has an active or past medical history of leptomeningeal disease.
• Participant has spinal cord compression that has not been definitively treated with  surgery or radiation or requires steroid treatment within 2 weeks prior to randomization.
• Participant has an active or past medical history of interstitial lung disease  (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis.
• Participant has known allergy, hypersensitivity, or intolerance to the excipients used  in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to  the use of osimertinib.
• Participant has symptomatic brain metastases. A participant with asymptomatic or  previously treated and stable brain metastases may participate in this study